Ta Win Holdings Berhad (KLSE:TAWIN) plans to acquire about 30% of ROYCE Pharma Manufacturing Sdn Bhd, according to sources. "The deal could be announced as early as this week. The one-third stake in Royce Pharma is estimated to be worth around MYR 15 million to MYR 20 million," a source familiar with the matter tells The Edge. Meanwhile, another source says Main Market-listed Ta Win may increase its shareholding in Royce Pharma at a later stage. "The existing shareholders are divesting their stakes in Royce Pharma. If they want to sell more [shares] in the future, Ta Win will be happy to take up their stakes," he says. Even so, The Edge has learnt that any acquisition of a majority stake in a pharmaceutical company is still subject to the approval of relevant ministries. A check on the Companies Commission of Malaysia (SSM) website reveals that Royce Pharma has two major shareholders: Poly Laboratories Sdn Bhd, which owns 53.8% of the company, and Jelita Serbaneka Sdn Bhd, which owns the remaining 46.2%. It is not immediately known whom Ta Win will acquire the 30% Royce Pharma stake from. It remains to be seen how Ta Win will fund the acquisition of Royce Pharma, given its net debt position of MYR 13.2 million as at Sept 30.